<DOC>
	<DOCNO>NCT01004419</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability vandetanib fulvestrant ; find maximum tolerate dose two drug ; evaluate response rate ass toxicity combination .</brief_summary>
	<brief_title>Trial ZD6474 Faslodex Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Current treatment metastatic non-small cell lung cancer ( NSCLC ) inadequate , median survival 8-12 month . Second-line therapy option include cytotoxic agent molecularly-targeted agent erlotinib . Nevertheless , 7-9 % patient respond standard second-line treatment . Treatment-related side effect cytotoxic drug decline performance status patient progress disease significant issue patient population . Novel approach molecularly-targeted agent clearly need . The combination vandetanib fulvestrant address potential interfere multiple interdependent growth-stimulatory pathway simultaneously . Recent work reveal cross-talk epidermal growth factor receptor ( EGFR ) estrogen receptor ( ER ) pathways . This clinical trial evaluate clinical interaction EGFR inhibitor , vandetanib , combination ER down-regulator , fulvestrant .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Pathologically/histologically confirm nonsmall cell lung cancer ( NSCLC ) , advance ( stage IIIB w/ effusion IV ) . Performance status 0 , 1 , 2 Brain metastasis must clinically stable treatment surgery and/or radiotherapy Must receive two prior systemic anticancer regimens recurrent/ metastatic disease , include one platinumcontaining regimen Prior radiotherapy , chemotherapy and/or treatment investigational agent allow provided patient recover treatmentrelated side effect grade ≤1 , least 3 week pass since last dose Required laboratory value demonstrate adequate bone marrow , kidney , liver , blood clot function . Negative pregnancy test woman childbearing potential within 7 day prior study entry Life expectancy 3 month Must tolerate intramuscular injection No prior concurrent use estrogen replacement therapy No concurrent use cytotoxic , immunologic , hormonal , investigational agent intend antitumor treatment NSCLC Prior therapy antiEGFR therapy gefitinib ( IRESSA ) , erlotinib ( TARCEVA ) , vandetanib ( ZD6474 , ZACTIMA ) , fulvestrant ( FASLODEX ) , aromatase inhibitor Clinically significant cardiac event myocardial infarction , superior vena cava syndrome , New York Heart Association ( NYHA ) classification heart disease ≥ 2 within 3 month entry History arrhythmia ( multifocal premature ventricular contraction ( PVCs ) , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) , symptomatic require treatment ( CTCAE grade 3 ) asymptomatic sustain ventricular tachycardia Presence leave bundle branch block Congenital long QT syndrome , 1st degree relative unexplained sudden death 40 year age History QTc prolongation result medication require discontinuation medication QTc Bazett 's correction unmeasurable , ≥ 480 msec screen ECG Potassium &lt; 4.0 mmol/L despite supplementation , potassium CTCAE grade 1 upper limit Serum calcium CTCAE grade 1 upper limit Magnesium normal range despite supplementation , CTCAE grade 1 upper limit Hypertension control medical therapy ( systolic blood pressure great 160 mm Hg diastolic blood pressure great 100 mm Hg ) Diagnosis active interstitial lung disease Currently active diarrhea may affect drug absorption Previous current malignancy histology within last 5 year , exception cervical carcinoma situ basal cell squamous cell carcinoma skin Concomitant use medication potent inducer CYP3A4 allow within 2 week study study Any unresolved toxicity great CTC grade 1 previous anticancer therapy Major surgery within 4 week , incompletely heal surgical incision Women currently pregnant breast feed History bleed diathesis ( ie , disseminate intravascular coagulation [ DIC ] , clot factor deficiency ) History hypersensitivity active inactive excipients fulvestrant ( ie castor oil Mannitol )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>vandetanib</keyword>
	<keyword>ZD6474</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>faslodex</keyword>
	<keyword>phase 1</keyword>
</DOC>